9877 Stock Overview
A medical device company, engages in the research and development of interventional products for the treatment of structural heart diseases in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Jenscare Scientific Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$3.32 |
| 52 Week High | HK$22.30 |
| 52 Week Low | HK$1.40 |
| Beta | 0.54 |
| 1 Month Change | 14.48% |
| 3 Month Change | 37.19% |
| 1 Year Change | -78.96% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -88.25% |
Recent News & Updates
Shareholder Returns
| 9877 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | 6.8% | -1.6% | -0.5% |
| 1Y | -79.0% | -27.9% | 19.9% |
Return vs Industry: 9877 underperformed the Hong Kong Medical Equipment industry which returned -28.7% over the past year.
Return vs Market: 9877 underperformed the Hong Kong Market which returned 18.3% over the past year.
Price Volatility
| 9877 volatility | |
|---|---|
| 9877 Average Weekly Movement | 10.0% |
| Medical Equipment Industry Average Movement | 9.0% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in HK Market | 18.6% |
| 10% least volatile stocks in HK Market | 4.1% |
Stable Share Price: 9877 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 9877's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 241 | Shiwen Lv | www.jenscare.com |
Jenscare Scientific Co., Ltd., a medical device company, engages in the research and development of interventional products for the treatment of structural heart diseases in the People’s Republic of China. It offers LuX-Valve and LuX-Valve Plus, a transcatheter tricuspid valve replacement (TTVR) product for the treatment of severe tricuspid regurgitation and high surgical risk; and Ken-Valve, a transcatheter aortic valve replacement product candidate for the treatment of severe aortic regurgitation or combined with aortic stenosis. The company also develops JensClip, a clip-based transcatheter mitral valve (TMVR) repair system, and JensRelive, a TMVR transfemoral system to treat patients with severe mitral regurgitation; MicroFlux, a transcatheter device to treat heart failure with pressured ejection fraction; and SimuLock, a bionics left atrial appendage occluder system for cardiogenic stroke prevention.
Jenscare Scientific Co., Ltd. Fundamentals Summary
| 9877 fundamental statistics | |
|---|---|
| Market cap | HK$1.38b |
| Earnings (TTM) | -HK$317.58m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.4x
P/E RatioIs 9877 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9877 income statement (TTM) | |
|---|---|
| Revenue | CN¥0 |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥0 |
| Other Expenses | CN¥298.24m |
| Earnings | -CN¥298.24m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.71 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 4.9% |
How did 9877 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 07:22 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jenscare Scientific Co., Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ruili Bian | Citigroup Inc |
| Jiaqi Zhu | Zhongtai Securities Co. Ltd. |
| Muqing Xie | Zhongtai Securities Co. Ltd. |